If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
In the event of ixekizumab overdosage, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.
summary contains discussion of doses that are inconsistent with the
approved dose of ixekizumab. Please refer to Taltz summary of product
characteristics for full prescribing information.1
up to 180 mg have been administered subcutaneously in clinical trials
in adults without dose-limiting toxicity. Overdoses up to 240 mg,
subcutaneously in adults, have been reported without any serious
the event of overdosage, it is recommended that the patient be
monitored for any signs or symptoms of adverse reactions and
appropriate symptomatic treatment be instituted immediately.1
Taltz [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:March 09, 2020
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org